[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-371915-105":59,"doc-detail-371915-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","car-t-cell-therapy-targeting-muc17-in-gastric-tumors","CAR-T cell therapy targeting MUC17 in gastric tumors","","Chimeric antigen receptor (CAR)-T cell therapy has shown major success in blood cancers, but solid-tumor efficacy remains constrained by the challenge of finding antigens that are abundant on tumor cells while sparing vital normal tissues. This study identifies MUC17 as a candidate target in gastric cancer, develops MUC17-specific 4-1BB/CD3ζ CAR-T cells, and evaluates cytotoxicity, cytokine release, and in vivo xenograft activity to test antitumor function and safety.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/car-t-cell-therapy-targeting-muc17-in-gastric-tumors/371915/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/car-t-cell-therapy-targeting-muc17-in-gastric-tumors/371915.png","ImageObject",300,407,{"name":92,"@type":93},"awa","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is CAR-T cell therapy less effective in solid tumors like gastric cancer?","Question",{"text":112,"@type":113},"A key barrier is identifying suitable target antigens that are highly expressed on tumor cells while avoiding expression in life-sustaining normal tissues.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What target is proposed for CAR-T therapy in this study?",{"text":117,"@type":113},"The study proposes MUC17, a membrane-tethered mucin-type glycoprotein with minimal normal tissue expression and frequent upregulation in gastric cancers.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the main outcomes of the MUC17-specific CAR-T cells?",{"text":121,"@type":113},"They showed potent antigen-specific cytotoxicity and robust cytokine release in vitro, maintained sustained effector functions, and significantly suppressed tumor growth in vivo without detectable toxicity in tested xenograft models.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},371915,1790244339,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},3985747858093,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Open access Original research  \nTo cite: Park S, Ho CE, Birocchi F, et al. CAR-T cell therapy targeting MUC17 in gastric tumors. Journal for ImmunoTherapy of Cancer 2025;13:e013120 . doi:10 . 1136/ jitc-2025-013120  \n► Additional supplemental material is published online only. To view, please visit the journal online ([https://doi.org/10.1136/](https://doi.org/10.1136/)[ ](https://doi.org/10.1136/)[jitc-2025-013120](jitc-2025-013120)) .  \nAccepted 23 October 2025  \n© Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.  \n1Krantz Family Center for Cancer Research and Cellular Immunotherapy Program, Massachusetts General Hospital, Boston, Massachusetts, USA 2Harvard Medical School, Boston, Massachusetts, USA 3Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA  \nCorrespondence to  \nDr Marcela V Maus;  \n[mvmaus@mgh.harvard.edu](mvmaus@mgh.harvard.edu)  \nCAR-T cell therapy targeting MUC17 in gastric tumors  \nSangwoo Park  ,1,2,3 Cassidy E Ho  ,1,3 Filippo Birocchi  ,1,2,3 Alexandra N Wolff,1,2,3 Amanda A Bouffard  ,1,3 Christopher Kelly  ,1,3 Diego Salas-Benito  ,1,2,3 Giulia Escobar  ,1,2,3 Adele Mucci,1,3 Trisha Berger  ,1,3 Marcela V Maus  1,2,3  \nABSTRACT  \nBackground Chimeric antigen receptor (CAR)-T cell therapy has achieved significant success in hematologic malignancies; however, its efficacy in solid tumors remains limited. A major limitation is the difficulty in identifying suitable target antigens that are abundantly expressed on the surface of tumor cells while sparing life-sustaining normal tissues.  \nMethods We identified MUC17, a membrane-tethered mucin-type glycoprotein with minimal expression in normal tissues and frequent upregulation in gastric cancers, as a potential target for CAR-T therapy. We developed and validated MUC17-specific CAR-T cells incorporating a 4-1BB/CD3ζ signaling domain. In vitro assays assessed cytotoxicity, cytokine secretion, and T cell phenotypes across multiple gastric cancer cell lines, including CRISPR-mediated MUC17 knockout controls. In vivo efficacy was evaluated using NSG xenograft models. Results MUC17 CAR-T cells exhibited potent, antigenspecific cytotoxicity, robust cytokine release, and sustained effector functions characterized by enrichment of central memory phenotypes. In vivo, MUC17 CAR-T cells significantly suppressed tumor growth without signs of toxicity in GSU and ASPC-1 models.  \nConclusions These findings support MUC17 as a promising immunotherapeutic target for gastric cancer and demonstrate how targeting glycocalyx-associated antigens can expand the range of surface proteins amenable to CAR-T cell-based therapies in solid tumors.  \nINTRODUCTION  \nGastric cancer is recognized as the fifth most common cancer worldwide, with more than one million new cases annually and over 800,000 deaths worldwide.1 2 As gastric cancer progresses rapidly and often lacks early symptoms, most patients are diagnosed at advanced stages. Despite advances in therapeutic strategies for gastric cancer including chemotherapy, targeted therapies, and immune checkpoint blockade, the overall prognosis for patients with advanced gastric cancer remains poor, with median survival rarely exceeding 1 year.2 3 Specifically, conventional treatment typically involves surgical resection, chemotherapy, and radiation, but many patients  \n\n| WHAT IS ALREADY KNOWN ON THIS TOPIC |\n| --- |\n| ⇒ CAR-T cell therapy has revolutionized hematologic malignancies but remains limited in solid tumors. In gastric cancer, which accounts for over one million new cases annually with poor survival rates, a major barrier is the lack of safe, tumor-specific antigens. Several targets, such as Claudin 18.2, are under clinical investigation but have shown risks of ontarget off-tumor toxicity. Membrane-bound mucins form a dense glycocalyx in gastric tumors and are frequently upregulated y","cbCaigrHHCu3KZUg","https://ap.wps.com/l/cbCaigrHHCu3KZUg","pdf",5029934,12,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction","[{\"question\":\"Why is CAR-T cell therapy less effective in solid tumors like gastric cancer?\",\"answer\":\"A key barrier is identifying suitable target antigens that are highly expressed on tumor cells while avoiding expression in life-sustaining normal tissues.\"},{\"question\":\"What target is proposed for CAR-T therapy in this study?\",\"answer\":\"The study proposes MUC17, a membrane-tethered mucin-type glycoprotein with minimal normal tissue expression and frequent upregulation in gastric cancers.\"},{\"question\":\"What were the main outcomes of the MUC17-specific CAR-T cells?\",\"answer\":\"They showed potent antigen-specific cytotoxicity and robust cytokine release in vitro, maintained sustained effector functions, and significantly suppressed tumor growth in vivo without detectable toxicity in tested xenograft models.\"}]","CAR-T cell therapy targeting MUC17 in gastric tumors | PDF",1790193206,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c565724686d9248baa5a01a757316eb5.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/20e5935a57532ece9ec6a0d9be4036e3.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4fac759c0b586e73ec4411db5bbbf579.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/74a4b25b09d155d1c79b22be0edb8462.webp",980,1306]